Genmab Archives

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Infographics 21 Feb 2017

Infographic: The Biggest Biotech Company in Each European Country

We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest employers in Europe, where companies of all sizes strive to bring the most innovative technology to the market. To illustrate the dynamic biotech ecosystem in […]

February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 15 Aug 2016

Gilead licenses Danish Bispecific antibodies for the next HIV Cure

As an add-on to their previously secretive partnership, Genmab is now licensing its bispecific antibodies for Gilead‘s pursuit of an HIV cure for as much as €248M. At the top of the Pyramid of European Biotech value, Genmab is one of the success stories in Copenhagen’s Biotech ecosystem. Its technology for innovative antibodies has allowed it […]

August 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 12 Jul 2016

Which European Biotechs made it to the Billion-Euro Club in 2016?

Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how these have evolved. Just 9 European Biotech companies (private and public) are worth over one billion right now. Many of these were present last year. For […]

July 12, 2016 - 6 minutesmins - By Philip Hemme

cormorant interleukin 8 bms immuno oncology

News and Trends 7 Jul 2016

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant – a Biotech developing immunotherapies in a deal that could go up to €460M. Based at the Karolinska Institute Science Park in Stockholm (Sweden), Cormorant was a private Biotech focusing on cancer immunotherapies. Its main program was HuMax-IL8, which is currently in Phase […]

July 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

copenhagen biothec genmab symphogen zealand

Best in Biotech 3 May 2016

Here are 12 Biotechs you need to know in Copenhagen – Skål!

With its canals, the Little Mermaid and the oldest amusement park in the world, Copenhagen is at the heart of the world’s obsession with Scandinavia – and it has a biotech scene to match. Pharma and biotech play a strong role in Denmark’s economy. The country is home to some key companies in the field, including […]

May 3, 2016 - 6 minutesmins - By Denise Neves Gameiro

medicxi venture index fund uk genmab jjdc gsk fund

News and Trends 2 Feb 2016

New €210M Life Sciences Fund is Launched in UK

Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210M Fund including GSK and Johnson & Johnson Innovation. Medicxi Ventures is based in London, Geneva and Jersey and has been investing in the Life Sciences field for over 20 years. It comprises all of the legacy portfolio […]

February 2, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Aug 2015

Genmab’s Bispecific Antibodies Catch Another Big Fish

Genmab, the Danish company developing the DuoBody technology platform to create and develop bispecific antibody candidates, just signed another licensing agreement with a Big Pharma company. This time, Novo Nordisk has been caught in a potential $502 million (€453m) deal. The DuoBody technology involves three basic steps to generate stable bispecific human IgG1 antibodies. In the first step, […]

August 17, 2015 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us